Ratings by Raymond James (David Novak)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/9/2021 | Zymeworks | ZYME | Downgrade | Outperform (Strong Buy) |
18.95 (24.08) |
27.07% | Details | |
| 11/9/2021 | ZIOPHARM Oncology | ZIOP | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/10/2021 | ZIOPHARM Oncology | ZIOP | Downgrade | Market Perform (Outperform) |
2.27 (0.87) |
-61.67% | Details | |
| 4/29/2021 | Catalyst Biosciences | CBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2021 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2021 | Catalyst Biosciences | CBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/19/2021 | Zymeworks | ZYME | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/21/2020 | Catalyst Biosciences | CBIO | New Coverage | Outperform (N/A) |
6.50 (2.94) |
-54.77% | Details | |
| 3/3/2020 | ZIOPHARM Oncology | ZIOP | Maintain | Outperform (N/A) |
|
Details | ||
| 1/14/2020 | Zymeworks | ZYME | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/8/2020 | Leap Therapeutics | LPTX | Upgrade | Outperform (Market Perform) |
1.68 (2.06) |
22.62% | Details | |
| 11/25/2019 | Zymeworks | ZYME | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/15/2019 | Leap Therapeutics | LPTX | Downgrade | Market Perform (Outperform) |
1.15 (1.68) |
46.09% | Details | |
| 9/30/2019 | Zymeworks | ZYME | Upgrade | Strong Buy (Outperform) |
25.88 (18.95) |
-26.78% | Details | |
| 9/13/2019 | Leap Therapeutics | LPTX | New Coverage | Outperform (N/A) |
1.73 (2.06) |
19.08% | Details | |
| 8/23/2019 | ZIOPHARM Oncology | ZIOP | New Coverage | Outperform (N/A) |
5.13 (0.87) |
-83.04% | Details | |
| 4/26/2019 | Zymeworks | ZYME | Maintain | Outperform (N/A) |
|
Details | ||
| 11/27/2018 | Zymeworks | ZYME | Maintain | Outperform (N/A) |
|
Details |
